Why focus on asthma control rather than severity?
In many chronic diseases, treatment is based on the initial disease severity, an intrinsic and relatively static feature. Previously, asthma 'severity' was based on the initial clinical features. However, patients with similar symptoms had widely differing responses to treatment. Asthma is now perceived as a syndrome with several underlying pathophysiological processes which are variably modified by inhaled corticosteroid treatment.
Asthma severity is now defined by the level of treatment required to achieve best asthma control. 3 'Mild asthma' can be well controlled on low-dose inhaled corticosteroids, but 'severe asthma' requires high-dose combination therapy or is uncontrolled despite such treatment.
introduction Deaths from asthma have dramatically fallen in recent years, so asthma is now often perceived as a commonplace and rarely serious condition. However, treatment of asthma in Australia is not optimal. The majority of preventer prescriptions for asthma in adults (≥15 years) are for the highest potency combination of an inhaled corticosteroid and long-acting beta 2 agonist rather than a low-dose inhaled corticosteroid (≤400 microgram/day budesonide or equivalent) which alone should be sufficient for most patients. 1, 2 In addition, more than half of the people aged 15-34 years are dispensed these medications only once in a year. Most patients use their inhalers incorrectly, and only 22% of patients have a written asthma action plan. 1 Clinical outcomes and costs could be substantially improved if an evidence-based approach was taken to tailoring an individual's asthma assessment and management.
identifying the need for treatmenthow to assess asthma control Current asthma guidelines are based on assessment of the patient's level of asthma control. This is the sUMMArY Although asthma is one of the most common chronic conditions in Australia, current treatment often fails to reflect clinical practice guidelines.
Improving the patient's management first requires an assessment of how well their asthma is controlled.
Factors such as poor inhaler technique and poor adherence may contribute to poor asthma control. These need to be addressed before adjusting the patient's drug prescription.
Simple processes for step-up and stepdown adjustments of treatment are used to maintain good control while minimising adverse effects.
There should be an emphasis on shared decision-making to improve patient understanding and acceptance of treatment.
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Rational prescribing for ongoing management of asthma in adults when asthma is not well controlled Once or twice a year each patient's asthma control and risk factors should be reviewed, and treatment adjusted if necessary. Patients may also make shortterm adjustments for worsening asthma in accordance with their written action plan.
In general, clinical guidelines recommend that patients experiencing symptoms three or more times a week or with one or more exacerbations per year should commence regular low-dose inhaled corticosteroids, or step up their existing preventer treatment. However, before any step-up, some important factors should be considered.
Are the symptoms due to asthma?
Asthma symptoms are non-specific, and new symptoms may be due to other conditions such as rhinitis, cardiac failure or vocal cord dysfunction. 4
Is inhaler technique correct?
Most patients and health professionals have incorrect inhaler technique, but are unaware of this. 5 The only way to identify incorrect technique is to watch the patient using their inhaler.*
The inhaler device should not be changed simply because the patient's technique is incorrect. Education about inhaler technique takes only 2-3 minutes, but is often very effective in improving asthma control 6 and is valued by patients. A physical demonstration, either in person or by video, is essential to improve inhaler technique. 7 Checklists and videos are available on the National Asthma Council website. 5, 8 
Question adherence
Patients are often reluctant to admit to poor adherence. Permissive wording can assist, for example, 'Would you usually take your inhaler once or twice a week, or less, or more?'. Poor adherence should not be surprising in asthma, with intermittent symptoms that usually respond rapidly to a reliever inhaler. In Australia, these medications are cheaper and more readily available than preventer medications, and patients often perceive them as safer.
Poor adherence may be classified as either intentionalwhere the patient makes a reasoned choice that the drug's perceived risks outweigh its perceived benefits -or unintentional, due to forgetfulness 9 or cost 10 .
There are few easy solutions to poor adherence. For unintentional poor adherence, suggest an alarm, placing the inhaler next to the toothbrush, or simplifying the medication regimen. Cost may be an issue, even for patients with a concession card. 10 In this situation, consider the relative cost to the patient of different preventer options, and aim for regular daily use even if at a low dose. For intentional poor adherence, a discussion about perceived risks and benefits can identify key barriers. An agreed dose can be negotiated using shared decision-making and goal-setting strategies, with little increase in consultation times.
Other factors?
Before increasing treatment, consider if poor control is due to rhinosinusitis, smoking, occupational exposure, allergens or drugs such as beta blockers. For many triggers, reducing exposure is beneficial, but evidence for house dust mite avoidance strategies is limited. Breathing exercises can help to reduce anxietyrelated symptoms or reliever overuse, but they do not improve lung function or airway inflammation. 11 
Consider a therapeutic trial of step-up treatment
Consider a dose increase or add-on therapy only after dealing with other factors contributing to poor control. Handle any change as a therapeutic trial, and document the patient's level of asthma control before and after the change. Set a review date, for example 2-3 months, and agree on criteria for assessing the patient's response. 3 
Step-up options
For patients whose asthma is uncontrolled on lowdose inhaled corticosteroids, two different step-up regimens are available. One option is a conventional regimen of low-dose inhaled corticosteroid with a long-acting beta 2 agonist, with a short-acting beta 2 agonist for symptom relief. Currently, the Pharmaceutical Benefits Scheme requires that patients should first be stabilised on separate inhalers, rather than a combination inhaler. However, this requires an additional visit and may increase the chance that patients will only take the long-acting beta 2 agonist.
The other step-up is a combination of low-dose budesonide and eformoterol (100/6 or 200/6), used as both maintenance and reliever therapy. This is possible because budesonide/eformoterol has a similar onset of action to salbutamol. With this regimen, levels of asthma control are similar and the risk of exacerbations is reduced or similar, versus higherdose inhaled corticosteroid or inhaled corticosteroid/ long-acting beta 2 agonist. 12 probably explained by the more timely, albeit small, increase in anti-inflammatory and bronchodilator dose as soon as symptoms worsen. This regimen reduces the risk of adverse effects, but is not suitable for patients who habitually overuse short-acting beta 2 agonists, who poorly perceive airway obstruction, or who would be confused by a regimen change.
If further step-up treatment is required, moderate or high-dose combination therapy can be used, but long-term adverse effects should be considered. A few patients remain uncontrolled and should be referred for consideration of other add-on therapy.
when asthma is well controlled
Once symptoms are stable for three months and exacerbations are infrequent, step-down should be actively initiated in order to minimise the risk of adverse effects, such as osteoporosis and cataract. Clinicians may be concerned about destabilising previously well patients, but this may result in overprescribing, and reinforce patient concerns about high doses. It is helpful to explain that both the overall dose and risk of exacerbations can be lowered by gradually decreasing to a low, regular, daily dose, rather than by stopping and starting treatment.
How to step down
Maintenance treatment can be gradually reduced at intervals of around two months, with inhaled corticosteroid dose reduced by 25-50% each time. Each change should be treated as a therapeutic trial, with the level of asthma control documented. There are few studies on which to base recommendations, but it would be reasonable to check lung function after the dose of inhaled corticosteroid has been reduced by 50%, or more frequently for patients who are anxious or at greater risk. Patients should be advised to return to the previous dose or medication and contact the doctor if their asthma is consistently worse after a step-down.
reFerenCes
For patients taking conventional fixed-dose combination therapy, step down through the available formulations. This reduces the inhaled corticosteroid dose by around 50% each time, mostly without changing the dose of long-acting beta 2 agonist. For patients taking the budesonide/eformoterol combination as maintenance and reliever therapy, the maintenance dose can be reduced, with the as-needed doses providing an immediate safety net if the patient's control deteriorates.
Once the lowest dose of combination therapy has been reached, options are to shift to once-daily dosing, which can be an effective option when the inhaled corticosteroid dose is ≤400 microgram daily, or to withdraw the long-acting beta 2 agonist and treat with inhaled corticosteroid alone. 13
Conclusion
Stepping-up and stepping-down treatment for asthma is not substantially different from the treatment principles for hypertension or diabetes. Assess the patient's status, prescribe an appropriate starting medication, ensure that the patient knows how and when to take it, review the patient's response, then monitor and readjust the treatment over subsequent visits. Inhaler technique and adherence should be assessed at every visit.
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Note: The June issue will feature an article on written asthma plans.
Self-teSt queStionS
True or false?
1. The severity of a patient's asthma is determined by their symptoms and lung function at the time of diagnosis.
2.
Patients with newly diagnosed asthma should start treatment with a combination inhaler containing a corticosteroid and a long-acting beta 2 agonist.
Answers on page 71
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